LYEL News and Press, Lyell Immunopharma Inc. From 12/07/25

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-...

2025-11-13 12:35:50 ET More on Lyell Immunopharma Lyell Immunopharma buys exclusive global rights to colorectal cancer drug Seeking Alpha’s Quant Rating on Lyell Immunopharma Historical earnings data for Lyell Immunopharma Financial information for Lye...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal ...

2025-11-10 10:29:07 ET More on Lyell Immunopharma Seeking Alpha’s Quant Rating on Lyell Immunopharma Historical earnings data for Lyell Immunopharma Financial information for Lyell Immunopharma Read the full article on Seeking Alpha For further...

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trial LYL273 is a GCC-targeted CAR ...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translation...

2025-09-03 09:30:25 ET South San Francisco, CA - Lyell Immunopharma, Inc. (Nasdaq: LYEL) has announced the initiation of PiNACLE-H2H, a Phase 3 head-to-head clinical trial evaluating its next-generation CAR T-cell therapy, rondecabtagene autoleucel (ronde-cel), against existing CD19...

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) setting Ronde-cel is Lyell’s next-generation, dual-t...